LEC Eye Centre, 44-46, Persiaran Greenhill, 30450, Ipoh, Perak, Malaysia.
Int Ophthalmol. 2024 Jul 24;44(1):334. doi: 10.1007/s10792-024-03247-x.
To evaluate the clinical outcomes following bilateral implantation of the AcrySof™ IQ Vivity™ toric extended depth of focus (EDOF) intraocular lens (IOL).
Prospective interventional case series.
Patients with bilateral significant cataracts and pre-existing corneal astigmatism underwent cataract surgery and implantation with the AcrySof™ IQ Vivity™ toric IOL. Dominant eyes were targeted at emmetropia and non-dominant eyes at -0.50D. Primary endpoints were binocular uncorrected distance (UDVA), intermediate (UIVA at 66 cm) and near (UNVA at 40 cm) acuities at 3 months. Secondary outcomes were corrected distance (CDVA), distance corrected intermediate (DCIVA) and distance corrected near (DCNVA), refractive predictability, rotational stability, binocular defocus curve, contrast sensitivity, Questionnaire for Visual Disturbances (QUVID) and Visual Function Index (VF-14) questionnaire scores. All visual acuities were converted to logarithm of minimum angle of resolution (logMAR) for analysis.
30 patients underwent uneventful phacoemulsification. The mean binocular UDVA, UIVA and UNVA were 0.06 ± 0.12, 0.11 ± 0.10 and 0.26 ± 0.10 respectively. The mean refractive spherical equivalent (MRSE) for dominant and non-dominant eyes were - 0.07D ± 0.27 and - 0.12D ± 0.54 respectively. 92.4% of dominant eyes and 84.6% of non-dominant eyes within 0.50D of target. The mean IOL rotation was 3.85° ± 5.09 with 86.7% of eyes with less than 5° of rotation. 26.7%, 20% and 36.7% of patients reported starbursts, haloes and glare respectively. The mean VF-14 score was 91.77.
Bilateral implantation of the AcrySof™ IQ Vivity™ Toric IOL resulted in very good unaided visual acuities for far and intermediate distance with functional near vision. Dysphotopsias were reported but despite this, a high level of visual function was achieved.
评估双眼植入 AcrySof™ IQ Vivity™ 散光延长景深(EDOF)人工晶状体(IOL)后的临床结果。
前瞻性干预性病例系列研究。
患有双侧明显白内障和先前存在角膜散光的患者接受白内障手术并植入 AcrySof™ IQ Vivity™ 散光 IOL。主导眼的目标是正视,非主导眼的目标是-0.50D。主要终点是术后 3 个月时双眼未矫正远距视力(UDVA)、中距(66cm 时的 UIVA)和近距视力(40cm 时的 UNVA)。次要结果包括矫正远距视力(CDVA)、远距矫正中距视力(DCIVA)和远距矫正近距视力(DCNVA)、屈光预测性、旋转稳定性、双眼离焦曲线、对比敏感度、视觉障碍问卷(QUVID)和视觉功能指数(VF-14)问卷评分。所有视力均转换为最小角分辨率对数(logMAR)进行分析。
30 例患者顺利完成了超声乳化白内障吸除术。双眼平均 UDVA、UIVA 和 UNVA 分别为 0.06±0.12、0.11±0.10 和 0.26±0.10。主导眼和非主导眼的平均等效球镜(MRSE)分别为-0.07D±0.27 和-0.12D±0.54。92.4%的主导眼和 84.6%的非主导眼在 0.50D 以内达到目标。平均 IOL 旋转度为 3.85°±5.09°,86.7%的眼旋转度小于 5°。分别有 26.7%、20%和 36.7%的患者报告有星爆、晕影和眩光。平均 VF-14 评分为 91.77。
双眼植入 AcrySof™ IQ Vivity™ 散光 Toric IOL 可获得远距和中距良好的裸眼视力,同时具有功能性近视力。尽管存在光觉障碍,但仍获得了较高的视觉功能水平。